Basak EA, et al. - In this investigation, researchers identified possible exposure-response relationships in nivolumab-treated patients with non–small-cell lung cancer (NSCLC). Between May 5, 2016, and August 1, 2017, patients with NSCLC who started second-line nivolumab therapy (3 mg/kg Q2W) and from whom serial blood samples, data on toxicity and results were collected. It was possible to evaluate 76 patients for analyzes. Investigators found that patients with NSCLC with nivolumab response had higher exposure to nivolumab than patients with progression, showing a potential exposure-response relationship.